EGFR and glioblastoma: The significance of binding reversibility is also highlighted by the lack of clinical efficacy of the reversible EGFR inhibitors gefitinib, erlotinib, and lapatinib in phase 1–2 trials of patients with glioblastoma (48–53), despite sharing similar biochemical features with osimertinib.